GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eiger BioPharmaceuticals Inc (OTCPK:EIGRQ) » Definitions » Cyclically Adjusted Book per Share

Eiger BioPharmaceuticals (Eiger BioPharmaceuticals) Cyclically Adjusted Book per Share : $357.79 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Eiger BioPharmaceuticals Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Eiger BioPharmaceuticals's adjusted book value per share for the three months ended in Dec. 2023 was $-9.772. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $357.79 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Eiger BioPharmaceuticals's average Cyclically Adjusted Book Growth Rate was 26.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-05-01), Eiger BioPharmaceuticals's current stock price is $2.20. Eiger BioPharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $357.79. Eiger BioPharmaceuticals's Cyclically Adjusted PB Ratio of today is 0.01.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Eiger BioPharmaceuticals was 1.10. The lowest was 0.01. And the median was 0.12.


Eiger BioPharmaceuticals Cyclically Adjusted Book per Share Historical Data

The historical data trend for Eiger BioPharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eiger BioPharmaceuticals Cyclically Adjusted Book per Share Chart

Eiger BioPharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 281.87 357.79

Eiger BioPharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 281.87 280.08 331.32 316.39 357.79

Competitive Comparison of Eiger BioPharmaceuticals's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Eiger BioPharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eiger BioPharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eiger BioPharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Eiger BioPharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Eiger BioPharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Eiger BioPharmaceuticals's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book= Book Value per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-9.772/129.4194*129.4194
=-9.772

Current CPI (Dec. 2023) = 129.4194.

Eiger BioPharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201403 1,327.682 99.695 1,723.544
201406 1,179.024 100.560 1,517.396
201409 1,583.446 100.428 2,040.557
201412 1,381.303 99.070 1,804.461
201503 1,097.337 99.621 1,425.568
201506 805.871 100.684 1,035.869
201509 685.042 100.392 883.120
201512 592.767 99.792 768.751
201603 232.158 100.470 299.051
201606 185.695 101.688 236.336
201609 186.908 101.861 237.476
201612 146.184 101.863 185.731
201703 110.760 102.862 139.356
201706 74.120 103.349 92.817
201709 44.929 104.136 55.838
201712 64.185 104.011 79.864
201803 41.945 105.290 51.558
201806 103.791 106.317 126.345
201809 53.106 106.507 64.531
201812 103.987 105.998 126.964
201903 79.139 107.251 95.497
201906 108.091 108.070 129.445
201909 87.767 108.329 104.854
201912 69.093 108.420 82.475
202003 52.772 108.902 62.715
202006 64.414 108.767 76.645
202009 87.370 109.815 102.968
202012 84.155 109.897 99.105
202103 111.504 111.754 129.129
202106 96.425 114.631 108.864
202109 78.996 115.734 88.337
202112 62.831 117.630 69.128
202203 72.050 121.301 76.872
202206 70.229 125.017 72.702
202209 53.392 125.227 55.180
202212 37.648 125.222 38.910
202303 23.866 127.348 24.254
202306 10.359 128.729 10.415
202309 -1.084 129.860 -1.080
202312 -9.772 129.419 -9.772

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Eiger BioPharmaceuticals  (OTCPK:EIGRQ) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Eiger BioPharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=2.20/357.79
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Eiger BioPharmaceuticals was 1.10. The lowest was 0.01. And the median was 0.12.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Eiger BioPharmaceuticals Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Eiger BioPharmaceuticals's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Eiger BioPharmaceuticals (Eiger BioPharmaceuticals) Business Description

Traded in Other Exchanges
Address
2155 Park Boulevard, Palo Alto, CA, USA, 94306
Eiger BioPharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.
Executives
Richard A Kayne 10 percent owner
Leen Kawas 10 percent owner 4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141
Ingrid Choong officer: Chief Business Officer 24645 SUMMERHILL AVE, LOS ALTOS CA 94024
William G Kachioff officer: CFO 4060 PORTE DE PALMAS, SAN DIEGO CA 92122
James Vollins officer: General Counsel C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARK LAKE AVE SUITE 225, RALEIGH NC 27607
Mayer Eldon C. Iii officer: Ex VP & Chief Commerc. Officer RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Lisa Kelly-croswell director C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Thomas John Dietz director C/O TRANSCEPT PHARMACEUTICAL, INC., 1003 W. CUTTING BLVD, STE 110, PT. RICHMOND CA 94804
Jeffrey S Glenn director 350 CAMBRIDGE AVENUE, SUITE 350, PALO ALTO CA 94306
David Apelian director C/O ACHILLION PHARMACEUTICALS, INC, 300 GEORGE STREET, NEW HAVEN CT 06511
Sriram Ryali officer: Chief Financial Officer C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO CA 94306
Christine Murray director C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Erik Atkisson officer: GC & Chief Compliance Officer C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO CA 94306
Kim Sablich director C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005
David A Cory director, officer: President and CEO 350 CAMBRIDGE AVENUE, SUITE 350, PALO ALTO CA 94306